The presence of soluble CD25 (the α-chain receptor of interleukin-2; IL-2) in pre-treatment serum of melanoma patients undergoing anti-CTLA-4 mAb therapeutic regimen has been shown to be an independent indicator of OS [41]. Here, CTLA4 is linked to melanoma.